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Asthma and COPD are two chronic inflammatory disorders of the airway characterized by
airflow limitation. While many similarities exist between these two diseases, they are patho-
logically distinct due to the involvement of different inflammatory cells; predominantly
neutrophils, CD8 lymphocytes in COPD and eosinophils and CD4 lymphocytes in asthma. Ciga-
rette smoking is associated with accelerated decline of lung function, increased mortality, and
worsening of symptoms in both asthma and COPD. Furthermore, exposure to cigarette smoke
can alter the inflammatory mechanisms in asthma to become similar to that seen in COPD with
increasing CD8 cells and neutrophils and may therefore alter the response to therapy. Ciga-
rette smoke exposure has been associated with a poor response to inhaled corticosteroids
which are recommended as first line anti-inflammatory medications in asthma and as an
add-on therapy in patients with severe COPD with history of exacerbations. While the main
proposed mechanism for this altered response is the reduction of the histone deacetylase 2
(HDAC2) enzyme system, other possible mechanisms include the overexpression of GR-b, acti-
vation of p38 MAPK pathway and increased production of inflammatory cytokines such as IL-2,
4, 8, TNF-a and NF-Kß. Few clinical trials suggest that leukotriene modifiers may be an alter-
native to corticosteroids in smokers with asthma but there are currently no drugs which effec-
tively reduce the progression of inflammation in smokers with COPD. However, several HDAC2
enhancers including low dose theophylline and other potential anti-inflammatory therapies
including PDE4 inhibitors and p38 MAPK inhibitors are being evaluated.
ª 2011 Elsevier Ltd. All rights reserved.04 648071.
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Tobacco was first introduced in the UK during the sixteenth
century by Sir Walter Raleigh and was promptly recom-
mended to treat many medical complaints, one being
respiratory diseases.1 In the seventeenth century, smoking
the leaves of the Datura plant that contain anticholinergic
compounds was a common practice recommendation to
treat airway diseases, and such “cures” were used until
adrenaline was first introduced for clinical use in the early
twentieth century. However, a few decades later,
increasing recognition of the harmful effects of tobacco
smoke on asthmatics in terms of both the development and
aggravation of the condition became apparent.2,3
Current estimates show that the prevalence of active
cigarette smoking in Europe is 29%, whereas the rate is lower
in the US at 21%.4,5 Accurate data are not available for the
proportion of patients with asthma who smoke, however,
available information suggest that the rates may be similar
to that of the general population.6 In the NHANES III data-
base, airflow obstruction was present in 14.2% of white male
and 13.6% white females who were current smokers.7
Both asthma and COPD are chronic inflammatory
disorders of the airways whose symptoms arise from
airflow obstruction. In both diseases, there is a gene-
eenvironmental interaction. In asthma, exposures to
environmental allergen are the main triggers for this
disease while cigarette smoking is the predominant cause
of COPD. Exposure to environmental tobacco smoke
(second-hand smoke) has been linked to asthma in early
childhood exposure and active smoking has been associated
with a rapid decline in lung function in asthma and COPD.8
Smoking cessation is therefore recommended as the
primary goal of the management in these patients. In
COPD, smoking cessation has shown to slow the decline in
lung function and to prolong survival.9,10While both asthma and COPD are characterized by
chronic airway inflammation, key inflammatory cells
involved in COPD (macrophages, neutrophils, CD8þ
lymphocytes) are different from those involved in asthma
(CD4þ Th2 lymphocytes, eosinophils) suggesting different
treatments may be required.11 Although asthma and COPD
represent two distinct diseases, these two conditions can
occasionally coexist. This may be particularly seen in
patients with asthma who have been exposed to cigarette
smoke, who can develop fixed airflow limitation and
a mixture of “asthma-like” and “COPD-like” inflammation.6
Furthermore, patients with COPD may have a mixed
inflammatory pattern with increased eosinophils similar to
that seen in asthma12 especially during exacerbations. It is
therefore not surprising that treatments for both these
diseases may often overlap.
In addition to its effect on the course of the two
diseases, cigarette smoke greatly reduces the efficacy of
some of the important treatment regimens currently
available for both conditions particularly inhaled cortico-
steroids.13e15 The purpose of this review is to highlight
potential mechanisms of how smoking affects the response
to the usual treatment regimens for these diseases, and
review potential alternative pharmacological therapies
which are currently available or under development.Effects of cigarette smoke on asthma and COPD
Lung function/disease course
Cigarette smoking is associated with accelerated decline of
lung function in asthmatics16,17 worsening asthma
severity,18,19 reduction of responsiveness to glucocorti-
coids13,14 and poor asthma control and higher hospital
admissions.20,21 Smokers with asthma also have a greater
Table 2 Effects of cigarette Smoke on clinical outcomes
in COPD.
Smokers Non-Smokers
FEV1 Decline (mL/5 years)
a 267 72
Mortality Risk Ratiob 2.2e24.7 1
a Figures are the cumulative 5 year average decline in FEV1 for
control group (smokers with COPD) and for those with sustained
cessation for 5 years (non-smokers with COPD).10
b Mortality risk ratios for cigarette smokers compared with
non-smokers vary markedly, as reported from 8 major
prospective studies.23
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mortality rates compared to non-smokers with asthma18
[Table 1]. In COPD, active cigarette smoking is the most
encountered risk factor and is associated with accelerated
decline in FEV1
10 and a higher mortality rate23 when
compared to patients with COPD who are non-smokers.24e26
[Table 2].
Airway inflammation
The exact mechanisms responsible for the adverse effects
seen in asthmatics and COPD who are active smokers are
uncertain but believed to be due to increased airway
inflammation and reduced corticosteroid responsiveness.27
Increased T-lymphocytes, mainly CD8 cells28 and macro-
phages within the airway wall and infiltration of peripheral
airways with mononuclear cells and macrophages29 have
been noted in normal smokers. Heightened sputum
neutrophil counts within bronchial secretions are also seen
in normal smokers and when this is elevated, increased
sputum concentrations of IL-8 are also observed.13 There is
also a positive correlation between neutrophil counts and
IL-8 levels with smoking history in pack years and negative
correlation with predicted FEV1. Reduced sputum eosino-
phil counts have been described in normal smokers
compared to non-smokers.30 Possible mechanisms for the
reduced eosinophil count could be the increased apoptosis
of activated eosinophils due to exposure the nitric oxide
found in cigarette smoke or the carbon monoxide, also
present, which may interact with heme proteins.31,32
The change in inflammatory mediators that occur in
smokers reinforces the idea that smokers with asthma
develop pathological features similar to COPD. Sputum
abnormalities, however, are not homogenous across all
patients as some groups of smokers with asthma have
similar findings to non-smokers.33 This suggests that
differences in intensity of smoking and duration of smoking
and phenotype of asthma may influence the inflammatory
profile seen in the airway of smokers with asthma.
A recent study reported reduced number of CD83 þ ve
mature dendritic cells and B lymphocytes in asthmaticTable 1 Effects of cigarette Smoke on clinical outcomes
in asthma.
Smokers Non-Smokers
FEV1 Decline (% change from FEV1
predicted age 18 and 40)a
17.8 10.1
Hospitalization Rates (%)b 58 42
Mortality Rates (OR)c 3.6 1
a A study of 4000 adults initially aged 18e30 yrs, who were
followed for over 10 yrs with serial spirometry measurements.
This was a subgroup within the study comparing asthmatics who
didn’t smoke with asthmatics who smoked at least 15 ciga-
rettes/day.16
b A study of 1847 patients between 18 and 54 yrs, who pre-
sented to the emergency department with acute asthma.
Current and former smokers together made up 58% of
admissions.21
c A study of 6 year mortality rate following a near-fatal
asthma attack with an age-adjusted odds ratio (OR).18smokers compared to those with the condition who never
smoked.34 These results were derived from one of the first
bronchial biopsy studies of the large airway of smokers and
non-smokers. The authors speculated that these results
may explain the higher number of lower respiratory tract
infections present in smokers with asthma. In animals,
smoking altered the IgE response and increased the sensi-
tization to allergens.35 Indeed, a recent study showed total
IgE levels were higher in smokers compared to non-smokers
with asthma.36 The authors suggested that smoking might
play a role in IgE secretion from B cells; however, the exact
mechanism is still unknown. The study demonstrated that
37.5% of asthmatic patients who were active or former
smokers showed decrease pulmonary function and
increased IgE, emphysema on high resolution computed
tomography and fixed airway obstruction. However, the
role on anti-IgE therapy in this population has not been
evaluated.
Clinical implications of cigarette smoke
exposure in asthma and COPD
The various changes in the inflammatory phenotype
observed in smokers with asthma and COPD have suggested
several potential mechanisms that new or existing treat-
ments can target. Data from several clinical trials (carried
out in asthmatics who were never smokers or former
smokers) have led to guidelines emphasizing the need for
inhaled corticosteroids as first line therapy in patients with
chronic asthma as the most effective anti-inflammatory
therapy for this condition.37,38 Studies have shown that
inhaled corticosteroids lead to a reduction in asthma
symptoms, improvement in lung function and quality of
life, and a reduction in airway inflammation and airway
hyper-responsiveness. Furthermore, studies have shown
that these drugs reduce the frequency and severity of
exacerbations and reduce asthma mortality.
However, these beneficial effects are reduced in asth-
matics who are active smokers as shown in several
studies.13,14,39,40 In one study, short-term inhaled cortico-
steroid treatment in active cigarette smokers failed to
cause significant changes in mean morning peak expiratory
flow (PEF), mean FEV1 and geometric mean PC20 to meth-
acholine when taking 1000ug of fluticasone propionate daily
for 3 weeks.13 Non-smokers who participated in this
randomized placebo-controlled trial showed significant
increases in these parameters as well as a decrease in
Table 3 Potential therapeutic options in smokers with
asthma and COPD.
Drugs class Examples
Smoking Cessation Nicotine Replacement
Therapy
Buproprion
Varenicline
ICS, ICS/LABA combination Fluticasone/Salmeterol
Budesonide/Formoterol
Mometasone/Formoterol
Long-acting Anticholinergics Tiotropium
Leukotriene Modifiers Montelukast
Zileuton
HDAC2 Enhancers Theophylline
Peroxynitrite Scavenger
Drugs
Macrolides
Peroxisome
Proliferator-Activated
Receptor Agonists
Rosiglitazone
Other Anti-Inflammatory
Agents
PDE4 Inhibitors
P38 MAPK inhibitor
TNF e a inhibitors
ICS Z Inhaled corticosteroids, LABA Z Long-acting beta2-
agonists, HDAC2 Z Histone deacetylase 2.
322 A. Tamimi et al.sputum eosinophils compared to placebo; findings not seen
in active cigarette smokers.
Furthermore, active smoking impairs the efficacy of
short-term oral corticosteroid treatment in chronic
asthma.14 A randomized, placebo-controlled, crossover
study assessed smokers with asthma, ex-smokers with
asthma, and never smokers with asthma who took pred-
nisolone (40 mg daily) or placebo for 2 weeks (all patients
had 15% reversibility of FEV1 after nebulized salbutamol
and a mean post-bronchodilator % predicted of more than
80%). Never smokers showed significant improvement in
FEV1 (237 ml), morning peak expiratory flow (PEF) (36.8 L/
min) and asthma control score (0.72). There were no
significant changes in any of the scores for smokers and in
subjects that were ex-smokers, treatment with predniso-
lone led to an improvement in morning and night PEF only
(29.1 and 52.36 L/min respectively).
There continues to be major controversies with regards
to treating COPD patients with inhaled corticosteroids.
While some studies demonstrated a significant effect of
inhaled corticosteroids in reducing the overall exacerbation
rate in patients with moderate-to-severe COPD (FEV1 <50%
predicted)41 and improving health status,42 arguments
against their as regular treatment are numerous and arise
from studies showing that their use does not reduce the
long term decline of FEV1 seen in these patients with
COPD,41,43,44 does not reduce overall mortality and
increases the probability of adverse effects including
pneumonia.45,46 As a result of the lack of evidence for their
benefits, and increasing evidence of potential detrimental
side effects, inhaled corticosteroids are not recommended
as first line therapy for patients with COPD, but are used as
add-on therapies in patients with severe and very severe
COPD to reduce exacerbations.
Taking into account all of these studies, the results
suggest cigarette smoke exposure in patients with asthma
or COPD is associated with relative resistance to cortico-
steroid therapy. Understanding the mechanism of this
resistance may help the development of treatment which
can restore corticosteroid sensitivity/which may improve
clinical outcomes.
Mechanisms of corticosteroid resistance
induced by cigarette smoke
Studies showing reduced effects of corticosteroids in
smokers with asthma and COPD have led to the implication
of various mechanisms involved in this resistance (Table 3).
HDAC2 dysfunction
Perhaps the most important mechanism that may explain
the relative corticosteroid resistance in smokers with
asthma and COPD is reduction in the enzyme histone
deacetylase 2 (HDAC2). Inflammatory genes activated in
both conditions lead to the acetylation of core histones.
This acetylation causes the opening up of the chromatin
structure, subsequent gene transcription and synthesis of
inflammatory proteins (Fig. 1).47,48 For corticosteroids to
exert their maximal effects in terms of pro-inflammatory
cytokine suppression, HDAC2 activity is required. It hasbeen previously shown that glucocorticoids act through the
glucocorticoid receptor (GR) by recruiting HDAC2 to the
activating transcription factor complex, preventing acet-
ylation.47 Smoking reduces the activity of HDAC2 in
inflammatory cells such as alveolar macrophages, which
may explain the increased expression of inflammatory
mediators seen in lavage samples of smokers.49 The
decrease in HDAC2 activity with smoking is possibly a result
of oxidative stress, which impairs its function as shown
in vitro in primary airway epithelial cells from healthy
volunteers.49 The nature of this oxidative stress is not
known, however, high levels of nitric oxide present in
tobacco smoke are thought to generate peroxynitrite.50
Peroxynitrite nitrates tyrosine residues on HDAC2 and
nitrotyrosine formation in the alveolar macrophages of
COPD patients has been documented.51 Drugs that increase
the level of HDAC2 in smokers show real promise as they
have the potential to restore corticosteroid sensitivity as
will be discussed.Glucocorticoid receptor b\
An increase in the number of neutrophils found in the
airway in heavy smokers who have asthma has also been
associated with poor corticosteroid response.52 It is
believed that overexpression of the glucocorticoid receptor
b isoform (GR-b) inhibits the action of the ligand-activated
glucocorticoid receptor alpha (GR-a), the functional iso-
form, through which the effects of glucocorticoids are
mediated.53e55 Since neutrophils have a higher number of
GR-b, this may explain the poor corticosteroid response
seen in smokers.
Figure 1 48 Possible mechanisms for decreased HDAC-2
activity in smokers with asthma and COPD. Cigarette smoke
produces superoxide anions and nitric oxide which with
inflammatory cells such as neutrophils produce peroxynitrite.
Peroxynitrite may lead to inactivation of HDAC-2 via nitration
and ubiquitination. Inactivation of HDAC-2 results in increased
inflammatory gene expression and reduced response to anti-
inflammatory actions of corticosteroids. Adapted from48 with
permission.
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In patients with corticosteroid-resistant asthma, airway T
cells were reported to have increased levels of IL-2 and IL-4
gene expression when compared to asthmatics who were
responsive to corticosteroids.56 The cytokines, IL-2 and IL-4
when combined in vitro, lead to reduced corticosteroid
response by causing a defect in peripheral blood mono-
nuclear cell glucocorticoid receptor binding affinity.57 This
is thought to be due to an increase in GR-b caused by higher
levels of IL2 and IL4.54 Similarly it has been shown that
smoking leads to an increase in the production of pro-
inflammatory cytokines IL4, IL-8 and TNF-a, both in vitro
and in vivo.13,58,59 While the precise mechanisms of how
these cytokines impair corticosteroid response are
unknown, it has been suggested to be due to raised GR-
b expression.60,61 Nuclear factor-Kb (NF-Kb) has also been
linked to corticosteroid unresponsiveness in Crohn’s
disease62 and is thought to play a similar role in smokers.
This is because bacterial lipopolysaccharide (LPS) present
in cigarette smoke is an activator of NF-Kb,63 and this
activated form is associated with the induction of pro-
inflammatory cytokines TNF-a and IL-8. Furthermore NF-
Kb can lead to phosphorylation of the GR, inhibiting GR-
a function and therefore, its ability to bind onto DNA and
lead to desired effect.64
The p38 mitogen-activated protein kinase (MAPK)
pathway is also thought to play a role in corticosteroid
insensitivity. This is because LPS stimulates bronchoalveo-
lar cells that lead to the activation of p38 MAPK at a more
rapid pace in smokers than in non-smokers.50 This leads to
phosphorylation of GR, which results in reduced affinity
between the corticosteroid and the receptor.65In summary, several mechanisms have been put forward
to explain the corticosteroid insensitivity identified in
asthmatic smokers and COPD patients. It is possible that not
a single one is responsible but several of them may be
acting together.
Current and future targets for therapy
Smoking cessation
Even though it is unclear whether or not smoking cessation
leads to improved corticosteroid responsiveness, the
importance of smoking cessation should be reinforced in
both these diseases. Studies show that smoking cessation is
associated with improved asthma control66,67 and reduced
COPD exacerbations. In one particular study, patients with
asthma who stopped smoking showed significant improve-
ment in lung function in the short term and a decrease in
neutrophil count when compared to asthma patients who
continued to smoke.68 Smoking cessation in COPD patients
can reduce progression8 and decrease the risk of all-cause
mortality, as shown after a 14.5 year follow up study by
Anthonisen et al.10 Although the benefits or stopping are
well known, it seems more useful to follow pharmacological
management guidelines from an early stage as cessation
rates are very low.69,70
Pharmacological therapies should supplement the
behavioural interventions in approaching patients who
want to quit smoking. First-line treatment as recommended
by guidelines should include a nicotine replacement
therapy, sustained release bupropion or varenicline unless
contraindications are present.71 Varenicline, a partial
agonist of selective neuronal nicotinic receptors is
approved for use as an aid to smoking cessation treatment
and shows significant effects in smokers with mild to
moderate COPD.72
Increasing dose of inhaled corticosteroids or
addition of a long acting bronchodilator
In smokers with asthma who are unable to stop smoking,
medication may be required in addition to inhaled corti-
costeroids or even as a replacement. Increasing the dose of
inhaled corticosteroids has been suggested.73 Tomlinson
et al showed that differences in morning PEF and the
number of asthma exacerbations between smokers and
non-smokers were reduced when patients were given
2000ug inhaled beclomethasone daily instead of 400ug. It
should be noted that this study had a small sample size and
showed a negative interaction test for a different effect of
smoking in the low versus high-dose inhaled corticosteroid
group. High doses of ICS have a minimal effect in patients
with COPD as they do not affect the rate of decline of lung
function nor do they decrease mortality.74 The only benefit
would be a reduction in frequency of exacerbations.
When combined with long-acting b2 agonists (LABA), an
inhaled corticosteroid is very effective in the treatment of
asthma and COPD, to a greater extent in the former. In
asthma, a post-hoc analysis of the Gaining Optimal Asthma
ControL (GOAL) study showed combination therapy with
fluticasone and salmeterol reduced exacerbation rates
324 A. Tamimi et al.compared to fluticasone alone.75 With regards to COPD,
subjects showed improved pre-treatment FEV1 significantly
more than placebo or either treatment alone, as well as
producing clinically significant improvement in health
status and a decrease in daily symptoms.76 In summary, the
scientific rationale for this combination takes into account
the different aspects of the pathophysiology of asthma/
COPD that they both affect.77 ICSs are known to suppress
chronic inflammation and reduce airway responsiveness,
while LABAs have bronchodilator actions, inhibit mast cell
mediator release and plasma exudation release.78 In addi-
tion, they may also reduce sensory nerve activation. Hence
the two drugs have complementary actions that would
otherwise be unachieved with either drug alone.
The effects of adding the long-acting anticholinergic
agent, tiotropium, to inhaled corticosteroids in non-
smokers with asthma adults whose disease was not
adequately controlled with a low dose of inhaled cortico-
steroids were examined in a trial which was just recently
published.79 The study was a triple blind, placebo
controlled, three-way crossover trial that aimed to
compare three treatments: doubling the dose of inhaled
glucocorticoid, adding a twice daily dose of LABA to
beclomethasone and adding a once daily dose of tiotropium
to beclomethasone. The addition of tiotropium resulted in
a larger improvement in both PEF (the primary outcome)
and FEV1 (secondary outcome) when compared to patients
who received double the dose of inhaled corticosteroid.
What was found to be more surprising was the addition of
tiotropium therapy was not inferior to the glucocorticoid
and LABA combination. These results may lead some clini-
cians to replace LABAs with tiotropium in patients who fail
to respond to low doses of glucocorticoids, such as those
seen in smokers with asthma. However, for more a defini-
tive answer, more studies are required to evaluate the
effects of tiotropium in smokers with asthma.Leukotriene modifiers
Leukotrienes are molecules believed to contribute to
airway obstruction seen in asthma. They are produced by
mast cells, alveolar macrophages and eosinophils and are
derived from the action of 5-lipoxygenase on arachidonic
acid.80e82 It is known that leukotrienes are able to mediate
bronchoconstriction,83 mucus secretion,84 the recruitment
of inflammatory cells85 and permeability of the microvas-
culature86 e all of these considered to be key components
of the physiology of asthma. Previous studies have shown
that leukotriene synthesis inhibitors or receptor antagonists
block the bronchospastic response seen in asthma patients
when exposed to allergens, exercise, cold dry air or
aspirin.87e90
Lazarus and colleagues demonstrated that in mild asth-
matics who smoked and who showed corticosteroid insen-
sitivity, montelukast produced a statistically significant
increase in morning PEF and a decrease in PEF variability in
smokers.33 Montelukast showed greater effects in smokers
than non-smokers. The rationale for this is that previous
studies have shown a dose-related increase in urinary
leukotriene E4 (LTE4) excretion in regular smokers.91
Furthermore, an increase in 5-lipoxygenase activity in theairways of smoker without asthma has been noted, as well
as an increase in urinary LTE4 caused by smoking in patients
with asthma which is not seen in healthy smokers or those
with COPD.92 The results seen from the study by Lazarus
and colleagues33 should be treated with caution as partic-
ipants only had very mild asthma and the improvement in
morning peak flow of montelukast in smokers with asthma
was small. These results need to be followed up by a larger
prospective study in order for leukotriene receptor antag-
onists to be recommended as first-line treatment of
smokers with asthma.
The role of leukotriene modifiers in COPD is limited
based on current clinical trials. However, a recent meta-
analysis looking at four placebo-controlled trials of COPD
patients treated with leukotriene antagonists, zafirlukast
and montelukast, came to the conclusion that these
patients showed a significant improvement in FEV1 and
FVC.93 The role of 5-lipooxygenase inhibitors such as
zileuton may be beneficial in smokers with asthma and in
COPD. Zileuton has additional effects in comparison to
leukotriene receptor antagonists, blocking the formation of
cysteinyl leukotrienes, hydroxyeicosatetraenoic acid and
leukotriene B4. A study by Israel et al showed patients with
asthma taking zileuton for three months experienced fewer
asthma exacerbations that required treatment with corti-
costeroids compared to placebo. Furthermore patients
taking zileuton saw an improvement in FEV1 by 15.7%
compared to an improvement of 7.7% seen in the control
group.94 A similar study carried out during the same time
period showed patients taking 600 mg and 400 mg of
zileuton experiencing greater improvements in FEV,
reduced blood eosinophil levels, improved morning PEF rate
and reduction in daytime and nocturnal symptoms
compared to the placebo group.95 In a recent study, sixty
patients with COPD were given oral zileuton in addition to
the usual treatment for exacerbation of COPD requiring
hospitilization. Despite being safe and reducing urinary
LTE4 levels, there was no difference in hospital length stay
or treatment failure compared to placebo. These results
may reflect the small nature of the study and larger trials
may be required to detect clinical improvement.96HDAC2 enhancers
Drugs which enhance HDAC2 provide real optimism for
reversing the corticosteroid insensitivity seen in COPD and
asthmatics who smoke. Lowedose theophylline can restore
the activity and increase expression of HDAC2 to normal in
alveolar macrophages in COPD patients, without side
effects that are experienced under high doses.97 These
effects are reversed with an HDAC2 inhibitor, confirming
theophylline does activate HDAC2 and does not restore
corticosteroid sensitivity via another mechanism. In
a murine model of short-term cigarette exposure to induce
inflammation similar to that seen in corticosteroid-resistant
COPD/asthma, low doses of theophylline effectively
reduced lung inflammation only when used in combination
with a corticosteroid.98 It is currently unknown how
theophylline activates HDAC2 but it is thought the activa-
tion occurs within the nucleus and via inhibition of PI3K as
LY-294002; a PI3K inhibitor mimics its action.99
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by oxidative/nitrative stress. Antioxidants available such as
vitamin C and E are not potent enough to reduce oxidative
stress in the lung sufficiently.99 Currently more potent
antioxidants and peroxynitrite scavenger drugs are being
developed.100 Curry powder contains a polyphenol, curcu-
min, which has been found to reverse corticosteroid
sensitivity by increasing HDAC2 expression levels to those
found in normal individuals in human monocytes exposed to
oxidative stress and cigarette smoke.101
Macrolides play a role in inhibiting NF-Kb and it has been
shown that a non-antibiotic macrolide increases HDAC2
activity which results in the reversal of corticosteroid
resistance, suggesting HDAC2 inhibits NF-Kb driven inflam-
mation.102 A recent study, in COPD patients, suggest that
the chronic administration (one year) of azithromycin is
associated with significant reduction in COPD exacer-
bation.103However, the chronic use of these agents in
smokers with asthma needs further studies.Peroxisome proliferator-activated receptor
agonists
Peroxisome proliferator-activated receptors (PPARs) are
a family of ligand-activated transcription factors that
belong to the nuclear hormone receptor family, of which 3
subtypes are known e PPAR-a, -g and - d. PPARs have been
shown to be related to glucocorticoid, retinoid and thyroid
hormone receptors.104 Experiments in vivo animal models
have shown that all 3 of the receptors when activated, lead
to anti-inflammatory and immunomodulatory effects in the
lung and other tissues, providing a potential novel target
for inflammatory diseases.105 The PPAR-g agonist rosiglita-
zone, a member of the thiazolidinediones class, was
generating the most interest as this drug was already being
used to treat diabetes. Although the main benefits of this
drug for diabetes were due to its insulin sensitizing effects,
additional benefits were thought to be due to anti-
inflammatory properties. Recent research has demon-
strated that rosiglitazone is able to bind to the glucocorti-
coid receptor ligand-binding domain and thereby alter gene
transcription.106 This may result in increased glucocorticoid
receptor activation which is otherwise lowered in smokers
as previously mentioned. A trial evaluating the effects of
rosiglitazone on the lung function of smokers with asthma
has recently reported its results.107 Rosiglitazone produced
improvements in prebronchodilator FEV1 relative to low
dose inhaled corticosteroids after 2 (164 ml, pZ 0.051) and
4 weeks of treatment (183 ml, p Z 0.051]. This improve-
ment was more substantial than previous studies that
assessed the effect of inhaled corticosteroids in asthmatic
smokers. Rosiglitazone also showed significant improve-
ments in both forced expiratory flow between 25 and 75% of
the forced vital capacity, suggesting a potential use in the
treatment of small-airway obstruction, of which few ther-
apies currently exist. The conclusion of this trial was that
the PPAR-g agonist showed improvements in lung function
measurements in smokers with mild to moderate asthma.
Limitations of the trial include the small number of subjects
and short duration of treatment. Further studies are
required to see how useful such PPAR-g agonists could be intreatment-resistant groups such as smokers with COPD and
asthma.
Other anti-inflammatory targets
Several selective phosphodiesterase- 4 inhibitors are
currently under development which may have an effect on
the neutrophilic inflammation seen in COPD. One such
agents is roflumilast.108 While roflumilast is now approved
for the treatment of COPD patients with severe disease and
with history of COPD exacerbations, it is not currently
approved for the treatment of asthma. However, there may
be a place for roflumilast in the treatment of smokers with
asthma, as when administered over 4 weeks, this drug
reduced the number of neutrophils by 36%.109 This needs
further exploration in future studies.
Inhibitors of the p38 MAP kinase cascade may have a role
in treating smokers with either condition that are cortico-
steroid insensitive as this would prevent the reduction of
activation of the GR by corticosteroids due to the action of
the MAPKs.65 In COPD patients, p38 MAPK is activated in
alveolar macrophages and regulates the expression of
inflammatory cytokines including IL-8 and TNF-a, and thus
may also play a role in asthmatic smokers.110 SD-282, an
inhibitor of p38, has been shown to be effective in sup-
pressing inflammation in smoking models of COPD in corti-
costeroid insensitivemice.111 Problems encountered include
severe adverse effects and toxicity that suggests they have
to be inhaled in order to reduce systemic exposure.
TNF-a levels are increased in both COPD and asthma and
are believed to cause neutrophilic inflammation in the
lungs. Infliximab, a recombinant human-murine chimeric
monoclonal antibody of TNF-a, caused a decrease in the
number of patients with exacerbations in symptomatic
moderate asthma and was well tolerated.112 These results
led the authors to recommend larger trials of therapy
against TNF-a, especially in patients with more severe
forms of asthma. The benefits of infliximab have failed to
pass onto patients with COPD. In a placebo-controlled trial
with over 200 COPD patients, Rennard and colleagues re-
ported no differences in symptom score (primary
endpoint), lung function, exercise capacity, as well as any
of the other secondary endpoints.113 This was unexpected
as the inflammatory pattern involving TNF-a in COPD is
similar to that found in rheumatoid arthritis and inflam-
matory bowel disease, where infliximab has been very
successful.114
Conclusions
Cigarette smoke adversely affects the course and response
to therapy in asthma and COPD. There is currently no
optimal drug therapy to effectively treat airway inflam-
mation in smokers with asthma or COPD, however, many
potential targets for future therapies exist. Since the
inflammatory phenotype seen in smokers with asthma is
somewhat similar to that seen in COPD, one type of medi-
cation may suppress the progression of inflammation in
both conditions. The most promising therapies are HDAC2
enhancers, which aim to reverse corticosteroid insensitivity
seen in smokers.
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